1 Nagtegaal, I. et al. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol 204, 183-192, doi:10.1002/path.1621 (2004).
2 Heald, R. J. & Ryall, R. D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1, 1479-1482 (1986).
3 Maas, M. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11, 835-844, doi:10.1016/S1470-2045(10)70172-8 (2010).
4 Glimelius, B., Tiret, E., Cervantes, A., Arnold, D. & Group, E. G. W. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6, vi81-88, doi:10.1093/annonc/mdt240 (2013).
5 Krook, J. E. et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324, 709-715, doi:10.1056/NEJM199103143241101 (1991).
6 Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351, 1731-1740, doi:10.1056/NEJMoa040694 (2004).
7 Beets-Tan, R. G. H. et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 28, 1465-1475, doi:10.1007/s00330-017-5026-2 (2018).
8 Delli Pizzi, A. et al. Rectal cancer MRI: protocols, signs and future perspectives radiologists should consider in everyday clinical practice. Insights Imaging 9, 405-412, doi:10.1007/s13244-018-0606-5 (2018).
9 Delli Pizzi, A. et al. Performance of diffusion-weighted magnetic resonance imaging at 3.0T for early assessment of tumor response in locally advanced rectal cancer treated with preoperative chemoradiation therapy. Abdom Radiol (NY) 43, 2221-2230, doi:10.1007/s00261-018-1457-8 (2018).
10 Lambregts, D. M. J. et al. A Pattern-Based Approach Combining Tumor Morphology on MRI With Distinct Signal Patterns on Diffusion-Weighted Imaging to Assess Response of Rectal Tumors After Chemoradiotherapy. Dis Colon Rectum 61, 328-337, doi:10.1097/DCR.0000000000000915 (2018).
11 Beets-Tan, R. G. & Beets, G. L. MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. Nat Rev Gastroenterol Hepatol 11, 480-488, doi:10.1038/nrgastro.2014.41 (2014).
12 Lambregts, D. M. et al. Diffusion-weighted MRI to assess response to chemoradiotherapy in rectal cancer: main interpretation pitfalls and their use for teaching. Eur Radiol, doi:10.1007/s00330-017-4830-z (2017).
13 Delli Pizzi, A. et al. Tumor detectability and conspicuity comparison of standard b1000 and ultrahigh b2000 diffusion-weighted imaging in rectal cancer. Abdom Radiol (NY) 44, 3595-3605, doi:10.1007/s00261-019-02177-y (2019).
14 Lambregts, D. M. J. et al. Long-term imaging characteristics of clinical complete responders during watch-and-wait for rectal cancer-an evaluation of over 1500 MRIs. Eur Radiol 30, 272-280, doi:10.1007/s00330-019-06396-1 (2020).
15 Rosa, C. et al. Reproducibility of rectal tumor volume delineation using diffusion-weighted MRI: Agreement on volumes between observers. Cancer Radiother 23, 216-221, doi:10.1016/j.canrad.2018.10.004 (2019).
16 Maas, M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29, 4633-4640, doi:10.1200/JCO.2011.37.7176 (2011).
17 van der Valk, M. J. M. et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391, 2537-2545, doi:10.1016/S0140-6736(18)31078-X (2018).
18 Haak, H. E. et al. Selection of Patients for Organ Preservation After Chemoradiotherapy: MRI Identifies Poor Responders Who Can Go Straight to Surgery. Ann Surg Oncol 27, 2732-2739, doi:10.1245/s10434-020-08334-8 (2020).
19 Burbach, J. P. M. et al. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: A systematic review and meta-analysis. Radiotherapy and Oncology 113, 1-9, doi:10.1016/j.radonc.2014.08.035 (2014).
20 Horvat, N. et al. MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. Radiology 287, 833-843, doi:10.1148/radiol.2018172300 (2018).
21 Petkovska, I. et al. Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy. Abdom Radiol (NY), doi:10.1007/s00261-020-02502-w (2020).
22 van Griethuysen, J. J. M. et al. Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer. Abdom Radiol (NY) 45, 632-643, doi:10.1007/s00261-019-02321-8 (2020).
23 Trebeschi, S. et al. Deep Learning for Fully-Automated Localization and Segmentation of Rectal Cancer on Multiparametric MR. Sci Rep 7, 5301, doi:10.1038/s41598-017-05728-9 (2017).
24 Chiacchiaretta, P., Cerritelli, F., Bubbico, G., Perrucci, M. G. & Ferretti, A. Reduced Dynamic Coupling Between Spontaneous BOLD-CBF Fluctuations in Older Adults: A Dual-Echo pCASL Study. Front Aging Neurosci 10, 115, doi:10.3389/fnagi.2018.00115 (2018).
25 Chiacchiaretta, P., Romani, G. L. & Ferretti, A. Sensitivity of BOLD response to increasing visual contrast: spin echo versus gradient echo EPI. Neuroimage 82, 35-43, doi:10.1016/j.neuroimage.2013.05.069 (2013).
26 Cirillo, S., Caulo, M., Pieri, V., Falini, A. & Castellano, A. Role of Functional Imaging Techniques to Assess Motor and Language Cortical Plasticity in Glioma Patients: A Systematic Review. Neural Plast 2019, 4056436, doi:10.1155/2019/4056436 (2019).
27 Metwali, H., Raemaekers, M., Ibrahim, T. & Samii, A. The Fluctuations of Blood Oxygen Level-Dependent Signals as a Method of Brain Tumor Characterization: A Preliminary Report. World Neurosurg 142, e10-e17, doi:10.1016/j.wneu.2020.04.134 (2020).
28 Ren, Y. et al. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features. J Magn Reson Imaging 49, 808-817, doi:10.1002/jmri.26240 (2019).
29 Caulo, M. et al. Data-driven grading of brain gliomas: a multiparametric MR imaging study. Radiology 272, 494-503, doi:10.1148/radiol.14132040 (2014).
30 Akinci D'Antonoli, T. et al. CT Radiomics Signature of Tumor and Peritumoral Lung Parenchyma to Predict Nonsmall Cell Lung Cancer Postsurgical Recurrence Risk. Acad Radiol 27, 497-507, doi:10.1016/j.acra.2019.05.019 (2020).
31 Mazurowski, M. A., Zhang, J., Grimm, L. J., Yoon, S. C. & Silber, J. I. Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology 273, 365-372, doi:10.1148/radiol.14132641 (2014).
32 Cox, R. W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29, 162-173, doi:10.1006/cbmr.1996.0014 (1996).
33 van Griethuysen, J. J. M. et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res 77, e104-e107, doi:10.1158/0008-5472.CAN-17-0339 (2017).
34 Traverso, A., Wee, L., Dekker, A. & Gillies, R. Repeatability and Reproducibility of Radiomic Features: A Systematic Review. Int J Radiat Oncol Biol Phys 102, 1143-1158, doi:10.1016/j.ijrobp.2018.05.053 (2018).
35 Magidson, J. in New Perspectives in Partial Least Squares and Related Methods Springer Proceedings in Mathematics & Statistics Ch. Chapter 3, 65-78 (2013).
36 Abdi, H. & Williams, L. J. in Computational Toxicology Methods in Molecular Biology Ch. Chapter 23, 549-579 (2013).
37 Wold, S., Ruhe, A., Wold, H. & Dunn, I. W. J. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses. SIAM Journal on Scientific and Statistical Computing 5, 735-743, doi:10.1137/0905052 (1984).
38 Chiarelli, A. M., Romani, G. L. & Merla, A. Fast optical signals in the sensorimotor cortex: General Linear Convolution Model applied to multiple source-detector distance-based data. Neuroimage 85 Pt 1, 245-254, doi:10.1016/j.neuroimage.2013.07.021 (2014).
39 Barlow, H. B. Unsupervised Learning. Neural Computation 1, 295-311, doi:10.1162/neco.1989.1.3.295 (1989).
40 Jolliffe, I. T. & Cadima, J. Principal component analysis: a review and recent developments. Philos Trans A Math Phys Eng Sci 374, 20150202, doi:10.1098/rsta.2015.0202 (2016).
41 Liu, R. & Gillies, D. F. Overfitting in linear feature extraction for classification of high-dimensional image data. Pattern Recognition 53, 73-86, doi:10.1016/j.patcog.2015.11.015 (2016).
42 Chiarelli, A. M. et al. Electroencephalography-Derived Prognosis of Functional Recovery in Acute Stroke Through Machine Learning Approaches. International Journal of Neural Systems, doi:10.1142/s0129065720500677 (2020).
43 Kearns, M. & Ron, D. Algorithmic stability and sanity-check bounds for leave-one-out cross-validation. Neural Comput 11, 1427-1453, doi:10.1162/089976699300016304 (1999).
44 Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680-2686, doi:10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c (1994).
45 Valentini, V. et al. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother Oncol 134, 110-118, doi:10.1016/j.radonc.2018.11.023 (2019).
46 Lupattelli, M. et al. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. Radiat Oncol 12, 139, doi:10.1186/s13014-017-0870-4 (2017).
47 Lambregts, D. M. et al. Long-term follow-up features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy. Dis Colon Rectum 54, 1521-1528, doi:10.1097/DCR.0b013e318232da89 (2011).
48 Bibault, J. E. et al. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. Sci Rep 8, 12611, doi:10.1038/s41598-018-30657-6 (2018).
49 Ma, X. et al. MRI-based radiomics of rectal cancer: preoperative assessment of the pathological features. BMC Med Imaging 19, 86, doi:10.1186/s12880-019-0392-7 (2019).
50 Yoon, J., Chung, Y. E., Lim, J. S. & Kim, M. J. Quantitative assessment of mesorectal fat: new prognostic biomarker in patients with mid-to-lower rectal cancer. Eur Radiol 29, 1240-1247, doi:10.1007/s00330-018-5723-5 (2019).
51 Visser, O. et al. The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in Greater Amsterdam. J Surg Oncol 95, 447-454, doi:10.1002/jso.20713 (2007).
52 Shaish, H. et al. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study. Eur Radiol, doi:10.1007/s00330-020-06968-6 (2020).
53 Jeon, S. H. et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat Oncol 14, 43, doi:10.1186/s13014-019-1246-8 (2019).
54 Cui, Y. et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 29, 1211-1220, doi:10.1007/s00330-018-5683-9 (2019).
55 Li, Z. Y. et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World J Gastroenterol 26, 2388-2402, doi:10.3748/wjg.v26.i19.2388 (2020).
56 Glynne-Jones, R. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 Suppl 4, iv22-iv40, doi:10.1093/annonc/mdx224 (2017).
57 Frydrych, L. M. et al. Rectal cancer sub-clones respond differentially to neoadjuvant therapy. Neoplasia 21, 1051-1062, doi:10.1016/j.neo.2019.08.004 (2019).
58 Canto, L. M. D. et al. Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response. Sci Rep 9, 8702, doi:10.1038/s41598-019-45151-w (2019).